

U.S. Application No. 09/874,141
Amendment dated April 12, 2005
In Reply to the official action of January 12, 2005
Attorney Ref. No. 037003- 0280632

Attachments:

Attached hereto is Form PTO-1449 listing the two references cited in the foregoing response, and copies of the cited references.

FORM PTO-1449 (modified)				Atty. Ref. No. 037003-0280632		Client Ref. No. 1995-30-0231CP2	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Applicant: Anderson et al.			
				Appln. No.: 09/874,141			
				Filing Date: June 6, 2001			
				Examiner: Phil Gambel		Group Art Unit: 1644	
Date: April 12, 2005				Page 1 of 1			
U.S. PATENT DOCUMENTS							
Examiner Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)			
AR							
BR							
CR							
DR							
ER							
FR							
GR							
FOREIGN PATENT DOCUMENTS							
		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
HR							
IR							
JR							
KR							
LR							
MR							
NR							
OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)							
	OR	Blair et al., "CD40 ligand (CD154) triggers a short-term CD4(+) T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis," J. Exp. Med., Feb. 21, 2000; 191(4):651-60.					
	PR	Blotta et al., "Cross-linking of the CD40 ligand on human CD4+ T lymphocytes generates a costimulatory signal that up-regulates IL-4 synthesis," J. Immunol., 1996; 156(9):3133-40.					
	QR						
	RR						
	SR						
	TR						
	UR						
	VR						
	WR						
	XR						
	YR						
	ZR						
	AAR						
Examiner					Date Considered:		
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							